Team Member

Dr. Pallavi Mahaddalkar
Post Doc

Phone: +49-89-3187-43160
Building/Room: Campus Neuherberg, building 3620, room 040a


Generation of Functional ß cells from Pluripotent Stem Cells for cell replacement therapies


Diabetes Mellitus (DM) is the leading metabolic disease of the 21st century affecting nearly 200 million individuals worldwide. This number is estimated to increase up to 416 million by the year 2030.

Two types of DM are clinically predominant in the modern world: Type I DM or insulin dependent diabetes resulting from the autoimmune destruction of the insulin producing ß cells and Type II DM or non-insulin dependent diabetes, which in contrast to type I results due to high blood glucose and insulin resistance.

A potential cure implemented to replace the lost or dysfunctional ß cells is via transplantation of whole donor pancreas or islets of Langerhans. Although this treatment has shown promising results, the scarcity of the donor material for cell therapy replacement and the risks of treatment with immunosuppressant drugs pose to be a limiting step for timely treatment.

To circumvent this bottleneck, human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) can provide as a promising avenue. My research focusses on establishing robust endoderm differentiation protocol from human embryonic stem cells in vitro to generate functional ß cells for cell replacement therapy.


Academic and Research Activities

June 2013- till datePost Doctoral Scientist, Institute of Diabetes and Regeneration, Garching Hockbrück. Supervisor: Prof. Dr. Heiko Lickert
November 2009 - June 2013Doctoral Studies (PhD), Institute of Molecular Medicine and Max-Planck Research group on Stem cell Ageing, Ulm, Germany. Supervisor: Prof. Karl Lenhard Rudolph
September 2008 - Sep 2009Master of Research (MRes), Medical and Molecular Sciences with specialization in Stem cells and Regeneration, Cancer Studies and Transplantation Sciences, Northern Institute of Cancer Research, Newcastle University, United Kingdom. Supervisor: Dr. Olaf Heindereich
September 2005 - Sep 2008Biomedical Sciences (B.Sc Hons), University of Central Lancashire, United Kingdom.


Alexander Korostylev#, P U Mahaddalkar#, Oliver Keminer, Kamyar Hadian, Kenji Schorpp, Philip Gribbon, Heiko Lickert. A high-content small molecule screen identifies novel inducers of definitive endoderm. Mol Metab. 2017 Apr 9

P U Mahaddalkar#, Kleger A#, SF Katz, A Lechel, JY Joo, K Loya, Q Lin, D Hartmann, S Liebau, JM Kraus, TCantz, HA Kestler, H Zaehres, H Scholer and KL Rudolph. (2012). Increased reprogramming capacity of mouse liver progenitor cells, compared with differentiated liver cells, requires the BAF complex. Gastroenterology 142:907-17. (#equally contributed) (Impact factor: 11.68)

P U Mahaddalkar#, Stefan Liebau#, Hans Kestler, Alexander Kleger (2012). A hierarchy in reprogramming capacity of somatic organ cells: what we know and what we need to know. Stem Cells Dev. 2013 Mar 1;22 (5):695-706. (#equally contributed) (Impact factor: 4.459)

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.